#1 Clinical Trials Search in Europe

Study on Early Treatment for Multiple Myeloma Relapse Using Carfilzomib, Bortezomib, Daratumumab, Lenalidomide, and Dexamethasone in Patients with MRD Negativity

1 1 1 1

What is this study about?

This clinical trial is focused on studying a disease called Multiple Myeloma, which is a type of cancer that affects plasma cells in the bone marrow. The study will explore the effectiveness of several treatments, including Carfilzomib (also known as PR-171), Bortezomib, Daratumumab (also known as HuMax-CD38), Lenalidomide, and Dexamethasone. These medications are used in different forms such as injections and capsules, and they work by targeting cancer cells in various ways.

The purpose of the study is to determine if starting treatment early, at the first sign of cancer cells returning in the bone marrow, can help patients live longer without the disease getting worse. The study will be conducted in two parts. In the first part, patients will receive standard treatments to see how many achieve a state called MRD negativity, which means no detectable cancer cells. In the second part, the study will compare two groups of patients: one group will start treatment early based on MRD results, and the other will follow standard guidelines for when to start treatment.

Participants in the study will receive different combinations of the medications mentioned above, either through intravenous administration, subcutaneous injection, or oral use. The study will monitor the patients’ health and response to the treatments over time, aiming to find the best approach to manage Multiple Myeloma effectively. The trial is expected to continue until 2032, providing valuable insights into the treatment of this disease.

1 joining the study

Upon joining the study, the patient is confirmed to have multiple myeloma and meets the eligibility criteria. This includes being between 18 and 75 years old, having measurable disease, and agreeing to follow the study protocol.

2 initial treatment phase

The patient receives initial treatment, which may include high-dose therapy and autologous stem cell transplant (ASCT). This phase aims to achieve minimal residual disease (MRD) negativity, meaning no detectable cancer cells in the bone marrow.

3 consolidation therapy

The patient undergoes consolidation therapy, which involves four cycles of treatment with a combination of medications: carfilzomib (intravenous), bortezomib (subcutaneous injection), daratumumab (subcutaneous injection), lenalidomide (oral capsules), and dexamethasone (oral tablets).

The goal is to further reduce cancer cells and achieve MRD negativity. The patient’s response is measured 30-45 days after the fourth cycle.

4 monitoring and assessment

The patient’s progress is monitored through regular assessments, including MRD testing using Euroflow technology. This helps determine the effectiveness of the treatment and the patient’s progression-free survival (PFS).

5 randomization and further treatment

If the patient achieves MRD negativity, they may be randomized into one of two groups for further treatment. One group receives early treatment at the first sign of cancer cells, while the other follows standard relapse treatment guidelines.

The objective is to compare the PFS and overall survival (OS) rates between the two groups.

6 ongoing evaluation

Throughout the study, the patient completes health-related quality of life forms and reports any adverse events. These evaluations help assess the impact of the treatment on the patient’s well-being.

7 study completion

The study is estimated to end in September 2032. The patient’s participation continues until the study’s conclusion or until they meet specific criteria for withdrawal.

Who Can Join the Study?

  • Patient must have been newly diagnosed with multiple myeloma, a type of blood cancer.
  • Patient should be eligible for high-dose therapy and ASCT (a type of stem cell transplant).
  • Patient must be older than 18 and younger than 75 years at the time of signing the consent form.
  • Patient must have a measurable disease, which means certain levels of specific proteins in the blood or urine that can be tracked.
  • Patient must provide voluntary written informed consent, agreeing to participate in the study.
  • Patient should have an ECOG performance status score of 0, 1, or 2, which indicates how well they can perform daily activities. A score of 3 is acceptable if it is due to myeloma.
  • Patient must be willing and able to follow the study’s schedule and requirements.
  • Females who can have children must have a negative pregnancy test before joining the study.
  • Females who can have children and males who are sexually active with such females must agree to use effective birth control during the study and for at least 28 days after the last dose of the study drug.
  • Male participants must also agree not to donate sperm for at least 28 days after the last dose of the study drug.
  • For Part 2, the patient must have achieved a state called MRD negativity, meaning no minimal residual disease is detected, after initial treatment.
  • Patient must have received initial treatment, including ASCT, according to local guidelines.
  • Patient should have an ECOG performance status score of 0, 1, or 2.
  • Patient must have had measurable disease at the time of diagnosis.

Who Cannot Join the Study?

  • Patients who have not been diagnosed with multiple myeloma, a type of cancer that affects certain cells in the bone marrow.
  • Patients who are not within the specified age range for the study.
  • Patients who are not able to follow the study procedures or attend required visits.
  • Patients who have other medical conditions that might interfere with the study or make participation unsafe.
  • Patients who are pregnant or breastfeeding.
  • Patients who are currently participating in another clinical trial.
  • Patients who have a history of certain other cancers or serious diseases.
  • Patients who have had a recent infection or illness that could affect the study results.
  • Patients who are unable to provide informed consent, which means they cannot understand the study and agree to participate.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name City Country Status
Oslo Universitetssykehus HF Oslo Norway

Other Sites

Site Name City Country Status
Universitetssykehuset Nord-Norge HF Tromsø Norway
St. Olavs Hospital HF Trondheim Norway
Helse Stavanger HF Stavanger Norway
Nordlandssykehuset HF Bodo Norway
Sørlandet sykehus Kristiansand Kristiansand Norway
Vilniaus universiteto ligonine Santaros klinikos VšĮ Vilnius Lithuania
Sykehuset Oestfold HF Kalnes Graalum Norway
Helse Forde HF Foerde Norway
Sykehuset I Vestfold HF Tonsberg Norway
Hmvog Npaxxevejceafw Hc Levanger Norway
Agyhopom Unblxbwqce Hlvnvmlv Lorenskog Norway
Hxfgp Bbiysl Ha Bergen Norway
Hayij Myygp Op Rwntgfz Hg Aalesund Norway

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
Lithuania Lithuania
Not recruiting
20.08.2024
Norway Norway
Not recruiting
20.08.2024

Trial locations

Investigated drugs:

Lenalidomide is a medication used in this trial to help manage multiple myeloma. It works by slowing or stopping the growth of cancer cells and is often used after initial treatments to maintain remission and prevent the cancer from returning.

Daratumumab is an antibody therapy that targets a specific protein on the surface of myeloma cells. It helps the immune system to identify and destroy these cancer cells, and is used in combination with other treatments to improve outcomes for patients with multiple myeloma.

Bortezomib is a medication that interferes with the growth of cancer cells by blocking a specific protein that helps them multiply. It is used in the treatment of multiple myeloma to reduce the number of cancer cells and help control the disease.

Dexamethasone is a type of steroid used in this trial to reduce inflammation and help manage symptoms associated with multiple myeloma. It is often used in combination with other cancer treatments to enhance their effectiveness.

Multiple Myeloma – Multiple myeloma is a type of blood cancer that affects plasma cells, which are a kind of white blood cell found in the bone marrow. In this disease, abnormal plasma cells multiply uncontrollably, leading to the production of a large amount of abnormal proteins. These proteins can cause damage to bones and other organs, such as the kidneys. As the disease progresses, it can lead to bone pain, fractures, and anemia due to the overcrowding of healthy blood cells. Patients may also experience frequent infections because the immune system is compromised. Over time, the disease can cause significant damage to the body’s organs and systems.

Trial ID:
2023-510215-18-00
Protocol code:
OMC01/19
NCT ID:
NCT04513639
Trial Phase:
Therapeutic use (Phase IV)

Other Trials to Consider

  • A study of etentamig and daratumumab compared to daratumumab, lenalidomide, and dexamethasone in adults with newly diagnosed multiple myeloma not eligible for transplant

    Recruiting

    1 1 1 1
    Investigated drugs:
    France Norway Spain

  • A study testing etentamig alone or with drug combinations in adult patients with multiple myeloma to assess safety and changes in disease activity

    Recruiting

    1 1 1
    Investigated drugs:
    Norway